Your browser doesn't support javascript.
The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).
Ceccarelli, Giancarlo; Alessandri, Francesco; Oliva, Alessandra; Borrazzo, Cristian; Dell'Isola, Serena; Ialungo, Anna Maria; Rastrelli, Elena; Pelli, Massimiliano; Raponi, Giammarco; Turriziani, Ombretta; Ruberto, Franco; Rocco, Monica; Pugliese, Francesco; Russo, Alessandro; d'Ettorre, Gabriella; Venditti, Mario.
  • Ceccarelli G; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Alessandri F; Covid Division, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy.
  • Oliva A; Covid Division, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy.
  • Borrazzo C; Department of Anesthesiology and Intensive Care, Sapienza University of Rome, Rome, Italy.
  • Dell'Isola S; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Ialungo AM; Covid Division, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy.
  • Rastrelli E; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Pelli M; Protect Medicine Division, Belcolle Hospital, Viterbo, Italy.
  • Raponi G; Protect Medicine Division, Belcolle Hospital, Viterbo, Italy.
  • Turriziani O; Protect Medicine Division, Belcolle Hospital, Viterbo, Italy.
  • Ruberto F; Intensive Care Unit, Department of medical and Surgical Science and Traslational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Rocco M; Microbiology Unit, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Pugliese F; Virology Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Russo A; Covid Division, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy.
  • d'Ettorre G; Department of Anesthesiology and Intensive Care, Sapienza University of Rome, Rome, Italy.
  • Venditti M; Intensive Care Unit, Department of medical and Surgical Science and Traslational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
J Med Virol ; 93(7): 4319-4325, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1118173
Semantic information from SemMedBD (by NLM)
1. teicoplanin TREATS COVID-19
Subject
teicoplanin
Predicate
TREATS
Object
COVID-19
2. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
3. teicoplanin TREATS Patients
Subject
teicoplanin
Predicate
TREATS
Object
Patients
4. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
5. CD69 protei INTERACTS_WITH C0145106
Subject
CD69 protei
Predicate
INTERACTS_WITH
Object
C0145106
6. Hospitalization TREATS Patients
Subject
Hospitalization
Predicate
TREATS
Object
Patients
7. teicoplanin TREATS COVID-19
Subject
teicoplanin
Predicate
TREATS
Object
COVID-19
8. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
9. teicoplanin TREATS Patients
Subject
teicoplanin
Predicate
TREATS
Object
Patients
10. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
11. CD69 protein, human|CD69 INTERACTS_WITH teicoplanin
Subject
CD69 protein, human|CD69
Predicate
INTERACTS_WITH
Object
teicoplanin
12. Hospitalization TREATS Patients
Subject
Hospitalization
Predicate
TREATS
Object
Patients
ABSTRACT
Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID-19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients. Fifty-five patients with severe COVID-19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei-COVID group), while 21 without teicoplanin (control group). Crude in-hospital Day-30 mortality was lower in Tei-COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei-COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei-COVID group and 57.1% of control group, without statistical difference. Serum C-reactive protein level was significantly reduced in Tei-COVID group compared to control group, but not other biochemical parameters. Finally, Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS-CoV-2, previously documented, is probably more effective at early clinical stages.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Hospital Mortality / Teicoplanin / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Observational study / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26925

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Hospital Mortality / Teicoplanin / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Observational study / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26925